Cardiac Biotech Solutions has signed a five-year exclusive distribution agreement with Noventis Medical covering Costa Rica, Panama, Colombia, and Argentina. The deal, valued at $600,000 for the distribution rights, grants Noventis a right of first refusal for additional Central and South American territories if it can match competing terms. The agreement expands the footprint for MyCardia AT, CBSC’s non-invasive ambulatory cardiac event monitoring platform, which integrates a lightweight wearable with cloud connectivity and mobile apps. The company reports U.S. regulatory clearance and ongoing submissions in Canada and China.
The strategic signal is clear: this is a capital-light push into high-need markets, trading near-term exclusivity for local execution and speed. The contract size suggests CBSC is prioritizing market access and channel control over guaranteed product volumes, effectively paying for committed distribution focus rather than booking material revenue today. The right of first refusal in particular is a double-edged choice—locking in an aligned partner across the region while limiting optionality if larger players later court CBSC with broader, pan-regional coverage.
Timing matters. Cardiovascular disease remains the leading cause of death across Latin America, and health systems are seeking cost-effective tools to detect arrhythmias earlier, shorten diagnostic delays, and avoid avoidable hospitalizations. Remote cardiac monitoring found fresh relevance during and after the pandemic, with payers and providers in the region increasingly open to decentralized diagnostics that can be deployed in outpatient and home settings. For health systems, the question is whether cloud-connected event monitoring can demonstrably reduce total cost of care; for patients and clinicians, whether adherence and data quality hold up outside controlled environments; for competitors, how quickly incumbents can localize offerings and bundle services with existing cardiology portfolios.
Execution will determine whether this entry turns into a durable presence. Commercial teams will need a pricing model that balances per-test affordability with recurring service revenue, credible service-level agreements, and logistics that work in markets with mixed public–private procurement and variable connectivity. Training, device supply, and maintenance capability will be decisive in public tenders and private cardiology networks. Medical Affairs should prioritize local real-world evidence that links detection yield to downstream interventions and outcomes, establishing value narratives for payers. Validation across diverse patient populations, integration into clinic workflows, and alignment with cardiology society guidance will be key. Regulatory registration remains a gating item in each country, with agencies such as INVIMA in Colombia and ANMAT in Argentina shaping timelines and evidence expectations.
This move also reflects a broader pattern in digital cardiology and diagnostics: smaller companies are leaning on regional distributors to extend reach while conserving cash amid uneven reimbursement environments in the United States and Europe. Exclusivity paired with rights of first refusal is becoming a common structure to secure partner commitment, but it places a premium on stringent performance metrics and transparent territory expansion criteria. As cloud-based devices enter new jurisdictions, data residency, cybersecurity, and interoperability with local electronic health record systems become as critical as device accuracy. AWS-backed connectivity offers scale, yet it must be matched to country-specific privacy frameworks and infrastructure realities.
The next six to twelve months will show whether CBSC can convert this beachhead into registered products, payer-aligned evidence, and first institutional wins. The pivotal questions for industry watchers: can a focused distributor-led model outpace larger incumbents and low-cost OEMs in Latin America, and will CBSC leverage this platform to springboard into major markets like Brazil while maintaining compliance, service quality, and profitable unit economics?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
